Hearing Aids May Slow Brain Inflammation, Study Finds

For years, researchers have known that untreated hearing loss is one of the most significant modifiable risk factors for dementia — the Lancet Commission on dementia prevention has estimated it accounts for about 8% of dementia cases globally. But "we know it's linked" and "we know why" are two very different things. A September 2026 secondary analysis of the landmark ACHIEVE randomized controlled trial, published in eClinicalMedicine, has now taken a meaningful step toward answering the second question. For the first time, researchers have found biomarker-level evidence that treating hearing loss with hearing aids slows a measurable sign of neuroinflammation in the brain. That's a big deal — and if you or someone you love has been putting off hearing aids, it's worth understanding what this actually means.

What the ACHIEVE Trial Found About Hearing Aids and Brain Health

The ACHIEVE trial was a large, well-designed randomized controlled trial that followed older adults aged 70–84 with untreated hearing loss. Participants were randomly assigned either to receive hearing aids along with audiological counseling, or to a health education control group. The main trial had already shown cognitive benefits for higher-risk participants. This new secondary analysis went a step further and looked at the blood.

Specifically, researchers tracked GFAP — glial fibrillary acidic protein — a biomarker that rises in the blood when there's neuroinflammation or stress on the brain's support cells. Over three years, GFAP naturally increased in both groups, as it tends to do with aging. But the hearing intervention group showed a significantly slower rise in GFAP compared to controls. In other words, treating hearing loss appeared to reduce the pace of brain neuroinflammation at a biological level — not just on a cognitive test score, but in the blood itself.

That distinction matters. It's one thing to say "hearing aid users score better on memory tests." It's another to show that their brains are producing less of a stress protein associated with neurodegeneration. The mechanism is becoming clearer.

Why Neuroinflammation Is Worth Taking Seriously

GFAP isn't a household name yet, but it's increasingly showing up in Alzheimer's and dementia research. When the brain is under stress — from injury, disease, or chronic sensory deprivation — the glial cells that support neurons become activated. They release GFAP into the bloodstream. Elevated GFAP has been associated with Alzheimer's pathology, cognitive decline, and faster brain aging.

The leading theory connecting hearing loss to brain inflammation goes something like this: when the auditory system is chronically deprived of input, the brain works harder to process degraded signals. That sustained cognitive effort — sometimes called "listening fatigue" — may contribute to chronic stress on brain tissue. Over years and decades, that stress accumulates. Hearing aids, by delivering cleaner sound signals, may reduce that burden and, in turn, slow the inflammatory cascade.

This isn't just theoretical anymore. It now has a blood test to back it up.

Who Benefits Most — and the Numbers That Caught Researchers' Attention

Not everyone with hearing loss benefits equally from intervention, which is part of why the ACHIEVE trial has generated so many follow-up analyses. A 2025 secondary analysis of the ACHIEVE data found that older adults with multiple risk factors for cognitive decline who received a hearing intervention experienced up to 61.6% slower three-year cognitive decline compared to controls. That's not a rounding error. For people who already have cardiovascular risk factors, a family history of dementia, or other markers of elevated risk, treating hearing loss may be one of the highest-yield interventions available.

The picture from a separate large-scale study adds more texture. A 2026 analysis published in Neurology using data from the ASPREE trial found that hearing aid use was linked to a meaningfully lower risk of developing dementia, even though it didn't significantly improve scores on standard cognitive tests. That gap — lower dementia risk without better test scores — suggests that hearing aids may protect the brain through pathways that routine cognitive assessments simply don't measure well. GFAP, it turns out, may be one of those pathways.

Zoom out, and the public health stakes are significant. Roughly two-thirds of adults over 70 have hearing loss. Of those, the majority don't use hearing aids — some because of cost, some because of stigma, some because they've been told "your hearing isn't bad enough yet." That last message may deserve a rethink.

The Gap Between Who Needs Hearing Aids and Who Has Them

Hearing aid adoption remains stubbornly low. Even after the FDA created a new over-the-counter hearing aid category in 2022 — making devices more accessible and affordable — most older adults with clinically significant hearing loss still don't use amplification. The reasons are understandable: the devices can feel conspicuous, they require adjustment, and some people genuinely don't notice how much they've been missing until they try them.

But the research trajectory is shifting the conversation from "quality of life" to "brain health." That reframe tends to motivate people differently. Struggling to follow a dinner table conversation feels like a social inconvenience. Learning that the same untreated hearing loss may be measurably accelerating neuroinflammation in your brain — that hits differently.

Video: Mayo Clinic Minute: How hearing issues may affect brain health -- Mayo Clinic

What Hearing Aids and Brain Health Research Means for Your Next Steps

You don't need to wait for your annual physical to take this seriously. Here's what the evidence suggests you can do right now:

Get a hearing evaluation if you haven't recently. Many audiologists offer baseline assessments, and over-the-counter options now make it possible to get screened and fitted without a prescription for mild-to-moderate hearing loss. If you're 60 or older and haven't had a hearing test in the past few years, schedule one. Think of it the way you think of getting your blood pressure checked.

Don't wait until hearing loss is "severe." The ACHIEVE trial enrolled adults with untreated hearing loss — not just profound impairment. The intervention effect on GFAP was seen in people with mild-to-moderate loss. Earlier treatment may mean more years of reduced inflammatory burden on the brain.

Track your overall health picture alongside hearing. Hearing loss rarely travels alone — it tends to co-occur with cardiovascular risk factors, poor sleep, and reduced physical activity, all of which also affect brain health. If you use SteadiDay, the app's free Apple Health integration lets you bring together data from your activity, sleep, and other health metrics in one place, so you can see how your habits are stacking up across the domains that matter most for aging well.

Talk to your doctor about your individual risk profile. If you have other risk factors for cognitive decline — high blood pressure, diabetes, a sedentary lifestyle, family history of dementia — the case for treating hearing loss proactively becomes even stronger. Bring the ACHIEVE research to the conversation if you need to. This is exactly the kind of evidence your doctor should know about.

Don't let stigma make the decision for you. Hearing aids have changed considerably in the past decade. Many are now small, Bluetooth-enabled, and rechargeable. The visible-hearing-aid stigma is a social calculation worth revisiting when the alternative is quietly accumulating neuroinflammation over years.

The Bigger Picture on Brain Protection

No single intervention prevents dementia. That's still true. But the science of dementia prevention increasingly looks like a collection of modifiable factors — sleep, exercise, blood pressure control, social connection, hearing — each contributing a meaningful slice. Treating hearing loss is now one of the best-evidenced items on that list, and the ACHIEVE biomarker data gives it a mechanistic plausibility that's hard to dismiss.

The brain is remarkably adaptive, but it's not infinitely forgiving. Years of chronic sensory deprivation leave a mark. The good news from this research is that intervention — even later in life, even with hearing aids — appears to slow that mark from deepening. That's not a cure. But it's something concrete you can act on, starting this week.

Common Questions

Can hearing aids actually reduce the risk of dementia, or just slow cognitive decline?

The evidence suggests both may be true, through different pathways. A 2026 analysis from the ASPREE trial found that hearing aid use was associated with a lower risk of developing dementia, even when standard cognitive test scores didn't significantly improve. The new ACHIEVE biomarker research adds a biological explanation: hearing aids appear to slow the rise of GFAP, a blood protein linked to neuroinflammation, which is one of the mechanisms associated with dementia development.

What is GFAP and why does it matter for brain health?

GFAP stands for glial fibrillary acidic protein. It's released into the bloodstream when the brain's support cells become stressed or inflamed — a process associated with Alzheimer's disease and other forms of neurodegeneration. Elevated GFAP levels are increasingly used in research as an early biomarker of brain stress. The ACHIEVE trial found that older adults with untreated hearing loss who received hearing aids had a significantly slower rise in GFAP over three years, suggesting reduced neuroinflammation compared to those who didn't receive treatment.

My hearing loss is mild — is it worth getting hearing aids at this stage?

The ACHIEVE trial included adults with untreated hearing loss that wasn't limited to severe impairment, and the biomarker benefit was observed in that population. Waiting until hearing loss becomes severe means years of potential neuroinflammatory burden that might have been reduced earlier. A hearing evaluation is a low-risk first step — it tells you where you stand and gives you and your doctor the information needed to make an informed decision.

Are over-the-counter hearing aids as effective as prescription devices for brain health?

The research so far doesn't draw a firm distinction between OTC and prescription devices in terms of brain health outcomes — the ACHIEVE trial used prescription hearing aids with audiological support. OTC devices, introduced in the U.S. in 2022, are designed for mild-to-moderate hearing loss and can be a more affordable entry point. For more significant hearing loss, or if you try OTC devices and don't notice improvement, seeing an audiologist for a fitted prescription device is worth the investment.